“Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis”, J of Skin, vol. 4, no. 6, p. s100, Oct. 2020, doi: 10.25251/skin.4.supp.100.